Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Palvella Therapeutics, Inc. (PVLA)

NewAmsterdam Pharma Company N.V. and Palvella Therapeutics, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Palvella Therapeutics, Inc. are of similar size ($2.3B and $2.3B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against −26.4%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −789.9%) and the higher return on invested capital (0.00% vs −23.1%). Across the 15 metrics below, Palvella Therapeutics, Inc. leads on 12 and NewAmsterdam Pharma Company N.V. on 3.

Valuation

Metric NAMS PVLA Biotechnology median
P/E n/m n/m 10.26
P/S 91.08 54.15 9.18
P/B 3.75 10.38 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 66.59 48.15 8.98
Earnings yield (8.88%) (3.08%) (34.89%)
Free cash flow yield (6.39%) (1.43%) (24.52%)

Profitability

Metric NAMS PVLA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (900.07%) 0.00% 0.00%
Net margin (789.94%) 0.00% 0.00%
Free cash flow margin (581.64%) 0.00% 0.00%
Return on equity (30.16%) (46.63%) (50.12%)
Return on assets (27.79%) (37.70%) (45.60%)
Return on invested capital (23.13%) 0.00% 0.00%

Growth

Metric NAMS PVLA Biotechnology median
Revenue growth (TTM) (26.41%) 146.67% 6.26%
EPS growth (last fiscal year) 32.81% 52.62% 29.88%
Revenue growth, 5-year CAGR — 8.03% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS PVLA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.76 21.18 4.89
Net debt to EBITDA 2.83 1.50 1.01

Dividend

Metric NAMS PVLA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NAMS PVLA Biotechnology median
Market cap 2.26b 2.26b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack